Key Highlights
- Human Metapneumovirus (HMPV) was first isolated in 2001 and belongs to the Pneumoviridae family.
- It produces cold‑like and flu‑like illnesses, with severe forms such as bronchitis and pneumonia primarily in children, seniors and immunocompromised patients.
- Transmission occurs through droplets, direct contact and contaminated surfaces; the acute infectious window lasts 3‑5 days and prior immunity offers limited protection.
- No specific antivirals or licensed vaccines exist; management is limited to supportive care.
- Recent clusters in Bengaluru and rising case counts across several Asian nations have heightened surveillance efforts.
Detailed Insights
Human Metapneumovirus is a single‑stranded RNA virus that circulates worldwide, showing a marked seasonality that peaks during winter and early spring. Clinical presentation ranges from mild upper‑respiratory signs—cough, fever, rhinorrhea, sore throat—to lower‑respiratory complications such as wheezing, bronchitis, pneumonia, and secondary ear infections. High‑risk cohorts include infants, adults older than 65 years, and individuals with compromised immune defenses.
The virus spreads efficiently via respiratory droplets expelled during coughing or sneezing and can persist on fomites, facilitating person‑to‑person transmission in crowded settings. After exposure, symptoms generally manifest within a few days, and viral shedding persists for approximately 3‑5 days. Although infection elicits an antibody response, it does not confer lasting sterilizing immunity, allowing reinfections in subsequent seasons.
Diagnostic confirmation relies on nucleic‑acid amplification tests performed on nasopharyngeal or oropharyngeal swabs. In severe cases, chest radiography or bronchoscopy may be required to assess pulmonary involvement. Because no virus‑specific therapeutics or vaccines are approved, clinical care focuses on supportive measures: supplemental oxygen for hypoxemia, intravenous fluid therapy to maintain hydration, and corticosteroids to attenuate airway inflammation.
Preventive strategies mirror those recommended for other respiratory pathogens: rigorous hand hygiene with soap, avoidance of facial contact with unclean hands, wearing masks in densely populated environments, self‑isolation while symptomatic, and routine disinfection of high‑touch surfaces.
Comparisons with SARS‑CoV‑2 (COVID‑19) reveal overlapping symptomatology and droplet‑borne transmission, yet diverge considerably in epidemiologic impact. Unlike COVID‑19, HMPV lacks approved vaccines or antiviral agents and typically follows a seasonal pattern rather than causing sustained worldwide pandemics.
Regional surveillance indicates a resurgence of HMPV cases in several Asian territories. China has reported increasing hospital admissions during the winter season, while Malaysia documented a 45 % surge in detections between 2023 and 2024. Japan, concurrently battling an influenza wave exceeding 94 000 cases, is also monitoring HMPV activity closely.